Loading asset research
OKYO Pharma Limited Ordinary Shares
OKYONasdaq · USD · StocksQuote as of · Exchange session not verified$1.39
-2.80%
Today
OKYO
Loading 1D prices…
Market cap
$73.5M
Volume
53.7K
52w high
$3.2052w low
$1.34Company profile
OKYO Pharma Limited Ordinary Shares
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
London, United Kingdom, United States
Employees
5
CIK
1849296
Session & valuation
Open$1.46
Previous close$1.43
Day high$1.47
Day low$1.39
30-day avg. volume71.7K
Outstanding shares52.5M
Diluted EPS-$0.24
Latest annual period
P/E (trailing)-5.79
P/E (forward)-2.12
Price / book5.96
Beta0.00
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| CSBRChampions Oncology Inc. Common Stock | $71M | $59.4M | -0.00% | -$0.08 | 0.00% | Unrated |
| BSEMBioStem Technologies Inc. Common Stock | $76.9M | $301.8M | +10.56% | $1.47 | +3.23% | Buy |
| KLRSKalaris Therapeutics Inc. Common Stock | $80.5M | $0.00 | — | -$2.85 | +2.42% | Buy |
| LONALeonaBio Inc. Common Stock | $65.2M | $0.00 | — | -$24.70 | +0.87% | Buy |
| PTHSPelthos Therapeutics Inc. Common Stock | $83.8M | $16.8M | -257.93% | -$23.04 | -2.36% | Buy |